| Identification | Back Directory | [Name]
IOMAZENIL | [CAS]
127985-21-1 | [Synonyms]
Iomazenil >=98% (HPLC)
Ethyl 7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-midazo[1,5-a][1,4]benzodiazepine-3-carboxylate
4H-Imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, 5,6-dihydro-7-iodo-5-methyl-6-oxo-, ethyl ester | [Molecular Formula]
C15H14IN3O3 | [MDL Number]
MFCD00899062 | [MOL File]
127985-21-1.mol | [Molecular Weight]
411.19 |
| Chemical Properties | Back Directory | [Boiling point ]
587.7±50.0 °C(Predicted) | [density ]
1.77±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble5mg/mL, clear (warmed) | [form ]
powder | [pka]
0.72±0.20(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
Iomazenil is a benzodiazepine receptor antagonist with partial inverse agonist activity. Iomazenil can assess the binding potential of central benzodiazepine receptors in the cerebral cortex and may reflect neuronal function in viable tissue. Iomazenil use is associated with improved cognitive function in adult patients with ischemic cerebral pathology after indirect revascularization surgery. Iomazenil demonstrated restoration of benzodiazepine receptor binding potential in the affected hemisphere after surgery on brain SPECT imaging[1]. | [Biological Activity]
Iomazenil (Ro 16–0154) is a benzodiazepine competitive antagonist and partial inverse agonist. Iomazenil has been shown to counteract the effects of alcohol. | [References]
[1] Recovery of Cortical Neurotransmitter Receptor Function and Its Impact on Cognitive Improvement after Indirect Revascularization Surgery Alone for Adult Patients with Ischemic Moyamoya Disease: 123I-Iomazenil Single-Photon Emission Computed Tomography Study DOI:10.1016/j.wneu.2022.05.118 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|